22P - Paclitaxel/ carboplatin/ bevacizumab in non-small cell lung cancer patients induces peripheral effector CD8 T cell proliferation that could be prone for treatment with checkpoint inhibitors
Authors
- D. Dumoulin (Barendrecht, Netherlands)
- P. De Goeje (Rotterdam, Netherlands)
- M. Poncin (Rotterdam, Netherlands)
- K. Bezemer (Rotterdam, Netherlands)
- H. Groen (Groningen, Netherlands)
- E. Smit (Amsterdam, Netherlands)
- A. Dingemans (Maastricht, Netherlands)
- A. Kunert (Rotterdam, Netherlands)
- R. Hendriks (Rotterdam, Netherlands)
- J. Aerts (Rotterdam, Noord Brabant, Netherlands)
Speakers
- D. Dumoulin (Barendrecht, Netherlands)
24P - A new bioinformatic pipeline allows the design of small, targeted gene panels for efficient TMB estimation
Authors
- P. Manca (Rome, Italy)
- I. Mallona (Zürich, Switzerland)
- D. Santini (Roma, Italy)
- G. Tonini (Roma, Italy)
- C. Rolfo (Baltimore, United States of America)
- M. Robinson (Zürich, Switzerland)
- F. Pantano (Roma, Italy)
Speakers
- P. Manca (Rome, Italy)
29P - Pretreatment T790M mutation detection by ultrasensitive PCR assay as predictor of efficacy in non-small lung cancer (NSCLC) patients treated with 1st or 2nd generation EGFR tyrosine kinase inhibitors (TKIs)
Authors
- O. Juan Vidal (Valencia, Spain)
- J. Simarro (Valencia, Spain)
- D. Lorente Estelles (Valencia, Spain)
- G. Pérez-Simó (Valencia, Spain)
- N. Mancheno (Valencia, Spain)
- R. Murria (Valencia, Spain)
- J. Gomez Codina (Valencia, Spain)
- B. Laiz (Valencia, Spain)
- S. Palanca (Valencia, Spain)
Speakers
- O. Juan Vidal (Valencia, Spain)
30P - Prognostic significance of IGF-1 signaling pathway in patients with advanced non-small cell lung cancer
Authors
- I. Kotsantis (Athens, Greece)
- P. Economopoulou (Athens, Greece)
- A. Psyrri (Athens, Greece)
- E. Maratou (Athens, Greece)
- D. Pectasides (Athens, Greece)
- H. Gogas (Athens, Greece)
- N. Kentepozidis (Athens, Greece)
- G. Mountzios (Athens, Greece)
- G. Dimitriadis (Athens, Greece)
- S. Giannouli (Athens, Greece)
Speakers
- I. Kotsantis (Athens, Greece)
31P - Do two lungs form an integrated immune system? Learning from BALF examination in lung cancer
Authors
- J. Domagala-Kulawik (Warsaw, Poland)
- T. Skirecki (Warsaw, Poland)
- D. Dziedzic (Warsaw, Poland)
- M. Polubiec-Kownacka (Warsaw, Poland)
- T. Kryczka (Warsaw, Poland)
- I. Kwiecien (Warsaw, Poland)
Speakers
- J. Domagala-Kulawik (Warsaw, Poland)
33P - Prognostic value of CD8-positive tumor stroma-infiltrating lymphocytes and PD-L1 positive tumor cells at initial biopsy in patients with locally advanced NSCLC treated with chemoradiotherapy
Authors
- K. Gennen (Munich, Germany)
- L. Käsmann (Munich, Germany)
- C. Eze (Munich, Germany)
- M. Dantes (Munich, Germany)
- O. Roengvoraphoj (Munich, Germany)
- J. Taugner (München, Germany)
- J. Neumann (München, Germany)
- A. Tufman (Munich, Germany)
- M. Orth (München, Germany)
- S. Reu (Würzburg, Germany)
- C. Belka (Munich, Germany)
- F. Manapov (Munich, Germany)
Speakers
- K. Gennen (Munich, Germany)
35P - Clinicopathological characteristics with genetic profiling and prognostic analysis of primary lymphoepithelioma-like carcinoma in Chinese south-eastern population
Authors
- Y. Shen (Shanghai, China)
- F. Hu (Shanghai, China)
- B. Zhang (Shanghai, China)
- B. Han (Shanghai, China)
Speakers
- Y. Shen (Shanghai, China)
36P - Can a BALF profile distinguish hot vs cold lung tumors?
Authors
- J. Domagala-Kulawik (Warsaw, Poland)
- D. Dziedzic (Warsaw, Poland)
- M. Polubiec-Kownacka (Warsaw, Poland)
- T. Kryczka (Warsaw, Poland)
- I. Kwiecien (Warsaw, Poland)
Speakers
- J. Domagala-Kulawik (Warsaw, Poland)
38P - Hedgehog pathway activation might mediate pemetrexed resistance in NSCLC cells
Authors
- Y. Liu (Munich, Germany)
- R. Kiefl (Munich, Germany)
- R. Huber (Munich, Germany)
- A. Tufman (Munich, Germany)
- D. Kauffmann-Guerrero (Munich, Germany)
Speakers
- Y. Liu (Munich, Germany)
41P - Diagnostic accuracy of droplet digital PCR (ddPCR) and amplification refractory mutation system PCR (ARMS-PCR) for detecting EGFR mutation in cell-free DNA of advanced lung cancer: A meta-analysis
Authors
- C. Li (Guangzhou, China)
- Q. He (Guangzhou, China)
- H. Liang (Guangzhou, China)
- J. He (Guangzhou, China)
- W. Liang (Guangzhou, China)
Speakers
- C. Li (Guangzhou, China)
44P - Temporal trends in treatment (Tx) and overall survival (OS) among patients (pts) with incident NSCLC in the UK: A real-oncology database analysis from the I-O Optimise initiative
Authors
- M. Snee (Leeds, United Kingdom)
- S. Cheeseman (Leeds, United Kingdom)
- M. Thompson (London, United Kingdom)
- M. Riaz (Leeds, United Kingdom)
- L. Lacoin (Ladeuze, Belgium)
- W. Sopwith (Leeds, United Kingdom)
- C. Chaib (Madrid, Spain)
- M. Daumont (Braine-L'Alleud, Belgium)
- J. Penrod (Princeton, NJ, United States of America)
- J. O'Donnell (Princeton, NJ, United States of America)
- G. Hall (Leeds, United Kingdom)
Speakers
- M. Snee (Leeds, United Kingdom)
45P - Treatment (Tx) patterns and overall survival (OS) in patients (pts) with stage IIIB–IV NSCLC in Portugal: An IPO-PORTO database analysis from the I-O Optimise initiative
Authors
- M. Soares (Porto, Portugal)
- L. Antunes (Porto, Portugal)
- P. Redondo (Porto, Portugal)
- M. Borges (Porto, Portugal)
- R. Hermans (London, United Kingdom)
- D. Patel (London, United Kingdom)
- F. Grimson (London, United Kingdom)
- R. Munro (London, United Kingdom)
- C. Chaib (Madrid, Spain)
- L. Lacoin (Ladeuze, Belgium)
- M. Daumont (Braine-L'Alleud, Belgium)
- J. Penrod (Princeton, NJ, United States of America)
- J. O'Donnell (Princeton, NJ, United States of America)
- M. Bento (Porto, Portugal)
- F. Goncalves (Porto, Portugal)
Speakers
- M. Soares (Porto, Portugal)